FDA statements raise concerns about the use of compounded GLP-1s and plan to enforce marketing restrictions
Pharmacokinetic Uncertainties Smaller doses may behave differently than expected: Absorption variability: Smaller volumes may have different kinetics Injection site effects: Multiple sites per week increase variability Threshold effects: Minimum concentration needed for efficacy unknown Receptor occupancy: May need sustained levels for full effect 4
Diabetes Care 47(10):17181730 Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM et al (2021) Healthy weight loss maintenance with Exercise, Liraglutide, or both combined
According to a clinical research plan updated by the company in early 2024, Lilly will conduct multiple Phase 3 clinical trials for Retatrutide over the next three years, with targeted indications primarily including obesity, chronic kidney disease, and type 2 diabetes
Common GLP-1 side effects often include nausea, constipation, diarrhea, vomiting, reflux, abdominal discomfort, reduced appetite, and fatigue
